Lurasidone Hydrochloride Tablet
Product Images NDC 47335-685

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 47335-685). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-lurasidone-120mg-label (Spl Lurasidone 120mg Label)

Packaging label for Lurasidone Hydrochloride Tablets 120 mg oral tablets. The label indicates 30 tablets per container and includes the NDC 47335-579-83. The labeler is Sun Pharmaceutical Industries, Inc. Additional details include a barcode, storage information, and space for lot and expiration dates. The label instructs pharmacists to dispense with a medication guide.*

FDA Label Image

Spl-lurasidone-20mg-label (Spl Lurasidone 20mg Label)

Label for Lurasidone Hydrochloride Tablets 20 mg oral tablets. The label indicates prescription-only status with 30 tablets per bottle, distributed by Sun Pharmaceutical Industries, Inc. It includes a barcode, NDC 47335-578-83, and instructions to dispense with a medication guide.*

FDA Label Image

Spl-lurasidone-40mg-label (Spl Lurasidone 40mg Label)

Packaging label for Lurasidone Hydrochloride Tablets 40 mg oral tablets, containing 30 tablets. The label includes NDC 47335-684-83 and is marked for pharmacist dispensing with a medication guide. The labeler is Sun Pharmaceutical Industries, Inc. Additional elements include a barcode and placeholders for lot and expiration dates.*

FDA Label Image

Spl-lurasidone-60mg-label (Spl Lurasidone 60mg Label)

Label of Lurasidone Hydrochloride Tablets 60 mg oral tablets by Sun Pharmaceutical Industries, Inc. The label shows the product name, strength of 60 mg, quantity of 30 tablets, and pharmacist dispensing instructions. Includes barcode and NDC number 47335-639-83.*

FDA Label Image

Spl-lurasidone-80mg-label (Spl Lurasidone 80mg Label)

Label for Lurasidone Hydrochloride Tablets 80 mg oral tablets, containing 30 tablets per package. The label includes a barcode, NDC 47335-685-83, and instructs pharmacists to dispense a medication guide to each patient. The product is labeled by Sun Pharmaceutical Industries, Inc.*

FDA Label Image

Spl-lurasidone-chemical-structure (Spl Lurasidone Chemical Structure)

Chemical structure of Lurasidone Hydrochloride, the active ingredient shown as a detailed molecular formula with rings, bonds, and a hydrochloride salt group.*

FDA Label Image

Spl-lurasidone-figure1 (Spl Lurasidone Figure1)

A forest plot chart depicting the impact of other drugs on lurasidone pharmacokinetics, showing fold changes and 90% confidence intervals for Cmax and AUC when coadministered with strong CYP3A4 inhibitors (Ketoconazole 400 mg/day), moderate CYP3A4 inhibitors (Diltiazem 240 mg/day), and strong CYP3A4 inducers (Rifampin 600 mg/day, Lithium 600 mg BID). The x-axis represents the fold change relative to lurasidone alone.*

FDA Label Image

Spl-lurasidone-figure2 (Spl Lurasidone Figure2)

A forest plot chart showing fold change and 90% confidence intervals for the pharmacokinetic parameters (Cmax, AUC, or Ctrough) of various interacting drugs (Digoxin, Midazolam, Ethinyl Estradiol, Norelgstromin, Lithium) compared to the interactive drug alone. The x-axis represents the fold change relative to the interactive drug alone, ranging from -1.0 to 1.0.*

FDA Label Image

Spl-lurasidone-figure3 (Spl Lurasidone Figure3)

A pharmacokinetic chart titled 'Fold Change and 90% CI' showing the relative change in Cmax and AUC for Lurasidone Hydrochloride across populations with varying renal and hepatic impairments, plus gender and race comparisons (Asian versus Caucasian). The x-axis represents change relative to reference, ranging from 0 to 6, while the y-axis categorizes impairment severity and population subgroups. Data points with confidence intervals illustrate differences in drug exposure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.